Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:NVNO NASDAQ:VANI NASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.97-6.8%$2.67$2.15▼$25.50$22.11M-0.47789,210 shs93,069 shsNVNOenVVeno Medical$4.33+4.7%$3.92$2.03▼$6.48$75.86M0.93112,021 shs57,060 shsVANIVivani Medical$1.63+7.1%$1.19$0.91▼$1.71$96.44M2.89100,466 shs232,709 shsZYXIZynex$2.29+0.2%$2.32$1.66▼$10.62$69.10M0.83175,446 shs73,536 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+9.91%+21.54%+26.91%+40.44%-87.36%NVNOenVVeno Medical-3.73%+4.29%-4.84%+73.53%-33.28%VANIVivani Medical+2.01%+19.69%+32.17%+44.76%+14.29%ZYXIZynex+8.06%-6.17%+8.57%+6.05%-75.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.9648 of 5 stars3.55.00.00.03.10.00.6NVNOenVVeno Medical0.6335 of 5 stars0.02.00.00.03.30.80.6VANIVivani Medical3.409 of 5 stars3.55.00.00.02.73.30.0ZYXIZynex2.0389 of 5 stars3.20.00.00.01.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 3.00Buy$22.83670.10% UpsideNVNOenVVeno Medical 0.00N/AN/AN/AVANIVivani Medical 3.00Buy$4.00145.70% UpsideZYXIZynex 2.33Hold$5.50140.70% UpsideCurrent Analyst Ratings BreakdownLatest ALUR, VANI, ZYXI, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.006/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/30/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.004/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$28.30M0.78N/AN/A($30.08) per share-0.10NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/AVANIVivani MedicalN/AN/AN/AN/A$0.30 per shareN/AZYXIZynex$192.35M0.36$0.26 per share8.64$1.12 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$26.15M-$12.50N/AN/AN/A-86.05%N/A-41.49%8/12/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-51.32%-48.23%7/30/2025 (Estimated)VANIVivani Medical-$23.49M-$0.43N/AN/AN/AN/A-133.07%-56.50%8/12/2025 (Estimated)ZYXIZynex$2.99M-$0.24N/A4.86N/A-4.30%-23.70%-6.23%7/23/2025 (Estimated)Latest ALUR, VANI, ZYXI, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALURAllurion Technologies-$0.65N/AN/AN/A$6.20 millionN/A8/12/2025Q2 2025VANIVivani Medical-$0.09N/AN/AN/AN/AN/A7/30/2025N/ANVNOenVVeno Medical-$0.28N/AN/AN/AN/AN/A7/23/2025Q2 2025ZYXIZynex-$0.20N/AN/AN/A$27.38 millionN/A5/14/2025Q1 2025ALURAllurion Technologies-$1.53$0.43+$1.96$0.20$5.50 million$5.58 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/A4/28/2025Q1 2025ZYXIZynex-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.091.88NVNOenVVeno MedicalN/A23.7723.77VANIVivani MedicalN/A2.402.40ZYXIZynex2.873.462.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%NVNOenVVeno Medical34.71%VANIVivani Medical6.78%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%NVNOenVVeno Medical16.00%VANIVivani Medical46.40%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.46 million6.74 millionOptionableNVNOenVVeno Medical3017.54 million14.73 millionOptionableVANIVivani Medical2059.24 million31.76 millionOptionableZYXIZynex77030.24 million15.34 millionOptionableALUR, VANI, ZYXI, and NVNO HeadlinesRecent News About These CompaniesZynex (ZYXI) to Release Quarterly Earnings on WednesdayJuly 16 at 3:50 AM | marketbeat.comRoyal Bank Of Canada Issues Pessimistic Forecast for Zynex (NASDAQ:ZYXI) Stock PriceJuly 15 at 11:37 AM | marketbeat.comZynex: New CEO Steven Dyson shares his vision – ICYMIJuly 12, 2025 | proactiveinvestors.comZynex: New CEO Steven Dyson shares his vision – ICYMIJuly 12, 2025 | proactiveinvestors.comZynex Shareholder Sues Board, Execs Over Insurer’s Payment PauseJuly 11, 2025 | news.bloomberglaw.comNZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 10, 2025 | globenewswire.comCritical Analysis: Zynex (NASDAQ:ZYXI) versus IM Cannabis (NASDAQ:IMCC)July 7, 2025 | americanbankingnews.comZynex CEO Thomas Sandgaard discusses leadership transition - ICYMIJuly 5, 2025 | proactiveinvestors.comZynex says Tricare payment suspension to remain in placeJuly 3, 2025 | msn.comZynex stock falls after Tricare extends payment suspensionJuly 2, 2025 | uk.investing.comTricare Temporary Payment Suspension UpdateJuly 2, 2025 | prnewswire.comZynex appoints Steven Dyson as new CEOJune 30, 2025 | msn.comZynex's (ZYXI) Buy Rating Reaffirmed at HC WainwrightJune 30, 2025 | marketbeat.comZynex taps Steve Dyson as chief executive officerJune 30, 2025 | proactiveinvestors.comZynex Announces Steven Dyson as New CEOJune 30, 2025 | prnewswire.comZynex awarded UK patent for non-invasive sepsis monitoring technologyJune 25, 2025 | proactiveinvestors.comZynex Announces Award of UK Patent for Non-Invasive Detection of SepsisJune 25, 2025 | prnewswire.comZynex Announces Workforce ReductionJune 24, 2025 | marketwatch.comHere’s Why Zynex (ZYXI) Fell in Q1May 23, 2025 | msn.comZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens BermanMay 21, 2025 | morningstar.comMFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexMay 21, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALUR, VANI, ZYXI, and NVNO Company DescriptionsAllurion Technologies NYSE:ALUR$2.96 -0.22 (-6.76%) Closing price 03:57 PM EasternExtended Trading$2.97 +0.01 (+0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.enVVeno Medical NASDAQ:NVNO$4.29 +0.16 (+3.87%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Vivani Medical NASDAQ:VANI$1.63 +0.11 (+7.11%) Closing price 03:59 PM EasternExtended Trading$1.64 +0.01 (+0.74%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Zynex NASDAQ:ZYXI$2.28 +0.01 (+0.22%) Closing price 03:59 PM EasternExtended Trading$2.28 -0.01 (-0.22%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
